Fig. 1 · Structure

Documents & Downloads

Dolutegravir (S/GSK1349572)

Cat. No. A11068 CAS 1051375-16-6

HIV integrase inhibitor

S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones.

In Stock

Publications for Dolutegravir

1 publication citing this product

  1. Lea El Khoury, .et al. , PeerJ Preprints, 2019, 7:e27833v1

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
HIV integrase (Cell-free assay) 2.7 nM

Cellular Effect

Cell Line Activity Value Description Reference
CHO IC50 > 100 μM Inhibition of human OATP1B1 expressed in CHO cells using [3H]estradiol 17beta-D-glucuronide as substrate by liquid scintillation counting analysis [PMID: 23132334]
HEK293 IC50 > 100 μM Inhibition of human OATP1B3 expressed in BacMam baculovirus virus infected HEK MSR2 cells using [3H]estradiol 17beta-D-glucuronide as substrate by liquid scintillation counting analysis [PMID: 23132334]
HEK-293T IC50 1.7 nM Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days [PMID: 23845180]
HEK-293T IC50 22 nM Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days in presence of human serum albumin [PMID: 23845180]
HOS EC50 1.6 nM Antiviral activity against HIV-1 harboring wild type integrase infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay [PMID: 24901667]
HOS EC50 11 nM Antiviral activity against INSTI-resistant HIV-1 harboring integrase R263K mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay [PMID: 24901667]
HOS EC50 13 nM Antiviral activity against INSTI-resistant HIV-1 harboring integrase G118R mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay [PMID: 24901667]
HOS EC50 3.6 nM Antiviral activity against raltegravir-resistant HIV-1 harboring integrase N155H mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay [PMID: 24901667]
HOS EC50 4.3 nM Antiviral activity against raltegravir-resistant HIV-1 harboring integrase Y143R mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay [PMID: 24901667]
HOS EC50 5.8 nM Antiviral activity against raltegravir-resistant HIV-1 harboring integrase G140S/Q148H double mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay [PMID: 24901667]
MDCK-II IC50 > 100 μM Inhibition of MDR1 (unknown origin) expressed in MDCK2 cells assessed as basolateral to apical transport of [3H]digoxin after 90 mins by liquid scintillation counting analysis [PMID: 23132334]
MDCK-II IC50 > 30 μM Inhibition of BCRP (unknown origin) expressed in MDCK2 cells assessed as basolateral to apical transport of [14C]cimetidine after 90 mins by liquid scintillation counting analysis [PMID: 23132334]
MDCK-II IC50 1.9 μM Inhibition of human OCT2 expressed in MDCK2 cells using [14C]metformin as substrate by liquid scintillation counting analysis [PMID: 23132334]
MT4 IC50 2 nM Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells after 4 to 5 days by bioluminescence assay [PMID: 23845180]
Sf9 IC50 > 100 μM Inhibition of human MRP2 expressed in baculovirus-infected Sf9 cell membrane vesicle using [3H]estradiol 17beta-D-glucuronide as substrate preincubated with vesicles for 5 mins prior to substrate addition by liquid scintillation counting analysis [PMID: 23132334]
Vero C1008 CC50 > 40 μM Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm) 10.1101/2020.04.03.023846
Vero C1008 EC50 22.04 μM Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days 10.1101/2020.04.03.023846

17 records · Scroll to view more

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1051375-16-6
Applications HIV integrase inhibitor
Formula C20H19F2N3O5
Molecular Weight 419.4
Synonyms GSK-1349572; S/GSK1349572
SMILES
C[C@@H]1CCO[C@@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 71 mg/mL (169.3 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Publications

1 publication citing this product

  1. Lea El Khoury, .et al. , PeerJ Preprints, 2019, 7:e27833v1

Added to your cart

View Cart Checkout
Loading...